Phil Skolnick
Director/Board Member chez Gilgamesh Pharmaceuticals, Inc.
Profil
Phil Skolnick is currently the Director at Gilgamesh Pharmaceuticals, Inc., Research Professor at Uniformed Services University of the Health Sciences, and Research Professor at NYU Langone Medical Center.
He was previously the Director-Therapeutics & Medical Consequences at National Institute on Drug Abuse from 2010 to 2017, President & Chief Scientific Officer at DOV Pharmaceutical, Inc. from 2007 to 2009, and is currently the Chief Scientific Officer at Opiant Pharmaceuticals, Inc. from 2017 to 2023.
Skolnick received his undergraduate degree from Long Island University in 1968 and his doctorate from George Washington University School of Medicine & Health in 1972.
Postes actifs de Phil Skolnick
| Sociétés | Poste | Début |
|---|---|---|
NYU Langone Medical Center
 NYU Langone Medical Center Hospital/Nursing ManagementHealth Services NYU Langone Medical Center is a premier academic medical center in the United States that is committed to excellence in patient care, medical education, and scientific research. The center is based in New York, NY, and has subsidiaries in the United States. The center offers a variety of non-degree educational programs, including the Pharmacy Technician Training Program and the PhD program at Vilcek Institute of Graduate Biomedical Sciences. NYU Langone Health's office of science and research is led by a team that is committed to supporting the excellence of their research enterprise. | Corporate Officer/Principal | 01/01/2001 |
| Uniformed Services University of the Health Sciences | Corporate Officer/Principal | - |
Gilgamesh Pharmaceuticals, Inc.
 Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Phil Skolnick
| Sociétés | Poste | Fin |
|---|---|---|
| OPIANT PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 02/03/2023 |
| National Institute on Drug Abuse | Corporate Officer/Principal | 01/02/2017 |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | President | 01/01/2009 |
Formation de Phil Skolnick
| Long Island University | Undergraduate Degree |
| George Washington University School of Medicine & Health | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
| National Institute on Drug Abuse | Government |
NYU Langone Medical Center
NYU Langone Medical Center Hospital/Nursing ManagementHealth Services NYU Langone Medical Center is a premier academic medical center in the United States that is committed to excellence in patient care, medical education, and scientific research. The center is based in New York, NY, and has subsidiaries in the United States. The center offers a variety of non-degree educational programs, including the Pharmacy Technician Training Program and the PhD program at Vilcek Institute of Graduate Biomedical Sciences. NYU Langone Health's office of science and research is led by a team that is committed to supporting the excellence of their research enterprise. | Health Services |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | Health Technology |
